Fumarate Hydratase-deficient Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Fumarate Hydratase-deficient Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma [Phase 2]
Phase 2 study of nivolumab in combination with cabozantinib in patients with non-clear cell renal cell carcinoma; the trial is currently act…
-
CLINICAL_TRIALS trial_result · 2024-12-27Clinical Trial Update: Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma [Phase 2]
A Phase 2 clinical trial evaluating talazoparib plus avelumab in metastatic renal cell carcinoma, including fumarate hydratase–deficient and…
-
CLINICAL_TRIALS trial_result · 2023-08-31Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC [Phase 2]
Phase 2 trial evaluating efficacy and safety of lenvatinib combined with tislelizumab in fumarate hydratase-deficient renal cell carcinoma.